HCS Pharma, expert in cellular imaging & in vitro assay development for High Content Screening (HCS) & Analysis (HCA) has just acquired BIOMIMESYS® Technology, a biomimetic hydrogel scaffold based on biofunctionalized hyaluronic acid with extracellular matrix components for 3D cell culture.

If you have already used BIOMIMESYS® products, be aware that they will be available again in early 2018! If you do not know yet this technology, please let us know your interest.

Using BIOMIMESYS® Technology, HCS Pharma will also provide its expertise in HCS/HCA to evaluate the efficacy, mode of action, and safety of your therapeutic molecules on 3D cell models.

Ask us for a TC to know more about our services and products.

BIOMIMESYS® Plates’ assets:

  • Natural biofunctionnalized scaffold
  • Ready-to-use and easy to handle for highly reproducible experiments
  • Compatible with HTS & HCS
  • Use also for long term cultures & in vivo transplantation
  • Ease of cell retrieval, PCR & WB analysis

Grégory MAUBON

Augmented Reality expert, curious about life, web 2.0, usage, technology and society, PhD in Astrophysics I like to Energize digital communities #AugmentedReality #barcamp #frenchtech #hootamb #Ignite #Diver #Dad #ExperimentalCook #ITprojetManager #Photographer #RolePlayer #Writer #Speaker #Animator and so on ...

1 Comment

3D-printed minifactories at ETH Zurich | HCS-pharma · December 21, 2017 at 3:20 pm

[…] In HCS Pharma we are very interested by this evolution and we are working on our biomimetic hydrogel… […]

Leave a Reply